Print Page      Close Window     

Investors

SEC Filings

6-K
OBSEVA SA filed this Form 6-K on 03/30/2018
Entire Document
 


LOGO

 

Robust late-stage pipeline for women’s reproductive health & pregnancy PRODUCT CANDIDATE OBE2109* Oral GnRH receptor antagonist NOLASIBAN Oral oxytocin receptor antagonist OBE022 Oral PGF2α receptor antagonist * Kissei developing for Asia PRECLINICAL    PHASE 1 PHASE 2PHASE 3STATUS & NEXTCOMMERCIAL MILESTONERIGHTS US/EU Phase 2b Endometriosis: EDELWEISS** Data mid-2018Worldwide US/EU Phase 3ex-Asia Uterine Fibroids: PRIMROSE1 & 2 Primary Endpoint Data 2H 2019 EU Phase 3 IVF: IMPLANT2EU***Live birth 4Q 2018 US Phase 3Worldwide IVF: IMPLANT3USInitiation 4Q 2018 EU Phase 2a Preterm Labor: PROLONGInterim DataWorldwide Late 2018 ** Patient recruitment completed *** Week10 pregnancy, primary endpoint met in Feb 2018